Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | SCN1A | P35498 | 16/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 16/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 6/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19927705 | 0.89 | SCN1A (0.38) | HSD11B1SCN1ASCN8ASCN5ASLC40A1 | |
| SCHEMBL29464874 | 0.89 | SCN1A (0.38) | HSD11B1SCN1ASCN8ASCN5ASLC40A1 | |
| SCHEMBL19925146 | 0.89 | HSD11B1 (0.39) | HSD11B1SLC40A1KDM4EALDH1A1HPGD | |
| SCHEMBL29464347 | 0.89 | HSD11B1 (0.39) | HSD11B1SLC40A1KDM4EALDH1A1HPGD | |
| SCHEMBL19968790 | 0.84 | SCN1A (0.39) | HSD11B1SCN1ASCN8ASCN5A | |
| SCHEMBL29464970 | 0.84 | SCN1A (0.39) | HSD11B1SCN1ASCN8ASCN5A | |
| SCHEMBL29464856 | 0.84 | SCN1A (0.39) | HSD11B1SCN1ASCN8ASCN5A | |
| SCHEMBL19925789 | 0.84 | SCN1A (0.39) | HSD11B1SCN1ASCN8ASCN5A | |
| SCHEMBL19925692 | 0.84 | SCN1A (0.38) | HSD11B1SCN1ASCN8ASCN5A | |
| SCHEMBL29464850 | 0.84 | SCN1A (0.38) | HSD11B1SCN1ASCN8ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2022-04-28 | — | — | US | disclosed |
| CN-113423702-A | N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use in the treatment of disease | 诺华股份有限公司 | 2021-09-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | CFTR, P2RY1, P2RX5 | HSD11B1 3742/4885SCN1A 32/4885SCN8A 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.